Breaking News

Israel Shoots Down Syrian Warplane Near Border, Army Says
Tweet TWEET

Infinity Announces Clinical and Preclinical Data to Be Presented at ASH 2013 Annual Meeting

  Infinity Announces Clinical and Preclinical Data to Be Presented at ASH 2013
  Annual Meeting

 – Company to Provide Overview of ASH Abstracts on Conference Call at 4:30 ET
                                   Today –

 – Company to Host ASH Investor Reception and Webcast on Sunday, December 8,
                                    2013 –

ASH 2013

Business Wire

CAMBRIDGE, Mass. -- November 7, 2013

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that new data
for IPI-145, the company’s oral inhibitor of phosphoinositide-3-kinase
(PI3K)-delta and PI3K-gamma, will be presented at the American Society of
Hematology (ASH) 2013 Annual Meeting, which is being held December 7-10 in New
Orleans, Louisiana.

Key results to be presented during the meeting include updated data from
Infinity’s Phase 1 study evaluating the safety, clinical activity and
pharmacokinetics of IPI-145 in patients with chronic lymphocytic leukemia
(CLL). Updated topline Phase 1 data on the activity of IPI-145 in patients
with indolent non-Hodgkin lymphoma (iNHL) and T-cell lymphoma will also be
reported. Additionally, the company will present preclinical and/or
translational data supporting the potential of IPI-145 across a range of
hematologic malignancies, including iNHL, CLL, diffuse large B‐cell lymphoma
(DLBCL) and T‐cell acute lymphoblastic leukemia (ALL).

Presentations of IPI-145 at ASH 2013 include the following:

Saturday, December 7, 2013, 5:30 p.m. – 7:30 p.m. CT (poster presentations)

Title: Treatment with the potent PI3K‐delta,gamma inhibitor IPI‐145 is
associated with rapid decreases in specific cytokines, chemokines and matrix
metalloproteinases in the serum of patients with chronic lymphocytic leukemia
and indolent non‐Hodgkin lymphoma
Presenter: Howard M. Stern, M.D., Ph.D., Infinity Pharmaceuticals, Cambridge,
MA
Location: Hall E

Title: The potent PI3K‐delta,gamma inhibitor, IPI‐145, exhibits differential
activity in diffuse large B‐cell lymphoma (DLBCL) cell lines
Presenter: Jeffery L. Kutok, M.D., Ph.D., Infinity Pharmaceuticals, Cambridge,
MA
Location: Hall G

Title: The potent PI3K‐delta,gamma inhibitor, IPI‐145, exhibits preclinical
activity in murine and human T‐cell acute lymphoblastic leukemia
Presenter: Xiaoyan Huang, M.D., MSc., Department of Hematopathology, MD
Anderson Cancer Center, Houston, TX
Location: Hall E

Sunday, December 8, 2013, 6:00 p.m. – 8:00 p.m. CT (poster presentation)

Title: Inhibition of PI3K-delta and -gamma isoforms by IPI-145 in chronic
lymphocytic leukemia overcomes signals from PI3K/AKT/S6 pathway and promotes
apoptosis
Presenter: Kumudha Balakrishnan, Ph.D., Department of Experimental
Therapeutics, MD Anderson Cancer Center, Houston, TX
Location: Hall E

Monday, December 9, 2013, 4:30 p.m. – 6:00 p.m. CT (oral presentation at 5:30
p.m. CT)

Title: Preliminary safety and efficacy of IPI-145, a potent inhibitor of
phosphoinositide-3-kinase-delta,gamma, in patients with chronic lymphocytic
leukemia
Presenter: Ian W. Flinn, M.D., Sarah Cannon Research Institute, Nashville, TN
Location: Room 295-296

Third Quarter Financial Results Conference Call/Webcast Reminder

As previously announced, Infinity will hold a conference call at 4:30 p.m. ET
today to review its third quarter 2013 financial results, share an update on
its business and provide an overview of the ASH abstracts referenced above. A
live webcast of the conference call can be accessed in the Investors/Media
section of Infinity's website at www.infi.com. To participate in the
conference call, please dial 1-877-316-5293 (domestic) and 1-631-291-4526
(international) five minutes prior to start time. The conference ID number is
34959052. An archived version of the webcast will be available on Infinity's
website for 30 days.

ASH Investor Reception and Webcast

Infinity will host a reception on Sunday, December 8, 2013, from 11:00 a.m. to
12:30 p.m. CT (12:00 p.m. to 1:30 p.m. ET) in New Orleans, Louisiana, to
review its PI3K-delta,gamma program in hematologic malignancies and discuss
the IPI-145 data being presented at the ASH 2013 Annual Meeting. The event
will be webcast and can be accessed in the Investors/Media section of
Infinity's website at www.infi.com. An archived version of the webcast will be
available on Infinity's website for 30 days.

About the Development of IPI-145 for the Treatment of Blood Cancers

Infinity is developing IPI-145, an oral inhibitor of Class I PI3K-delta,gamma.
The PI3Ks are a family of enzymes involved in multiple cellular functions,
including cell proliferation and survival, cell differentiation, cell
migration and immunity. The PI3K-delta,gamma isoforms are preferentially
expressed in leukocytes (white blood cells), where they have distinct and
mostly non-overlapping roles in immune cell development and function.
Targeting PI3K-delta and PI3K-gamma may provide multiple opportunities to
develop differentiated therapies for the treatment of hematologic malignancies
as well as inflammatory diseases.

Infinity is currently enrolling patients with refractory indolent non-Hodgkin
lymphoma (iNHL) in a Phase 2 study to evaluate the safety and efficacy of
IPI-145 (ClinicalTrials.gov Identifier NCT01882803). An investigator-sponsored
Phase 1b, open-label study of IPI-145 in patients with B-cell NHL, CLL and
T-cell lymphoma in combination with rituximab (a monoclonal antibody therapy),
bendamustine (a chemotherapy) or both rituximab and bendamustine is also open
for enrollment (NCT01871675). Additionally, a Phase 1 study of IPI-145 in
patients with advanced hematologic malignancies is ongoing (NCT01476657).
Infinity plans to begin enrolling a Phase 3 study of IPI-145 in patients with
relapsed/refractory CLL by the end of 2013.

About Infinity Pharmaceuticals, Inc.

Infinity is an innovative biopharmaceutical company dedicated to discovering,
developing and delivering best-in-class medicines to people with
difficult-to-treat diseases. Infinity combines proven scientific expertise
with a passion for developing novel small molecule drugs that target emerging
disease pathways. For more information on Infinity, please refer to the
company’s website at www.infi.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of
The Private Securities Litigation Reform Act of 1995. Such forward-looking
statements include those regarding the company’s expectations about: the
timing and type of data to be presented at the American Society of Hematology
2013 Annual Meeting; plans to initiate additional clinical trials; its ability
to execute on its strategic plans; and the therapeutic potential of PI3K
inhibition and IPI-145. Such statements are subject to numerous important
factors, risks and uncertainties that may cause actual events or results to
differ materially from the company’s current expectations. For example, there
can be no guarantee that Infinity will initiate clinical trials, enroll
patients, or report data in the time frames it has estimated, that any product
candidate Infinity is developing will successfully complete necessary
preclinical and clinical development phases or that development of any of
Infinity’s product candidates will continue. Further, there can be no
guarantee that any positive developments in Infinity’s product portfolio will
result in stock price appreciation. Management’s expectations and, therefore,
any forward-looking statements in this press release could also be affected by
risks and uncertainties relating to a number of other factors, including the
following: Infinity’s results of clinical trials and preclinical studies,
including subsequent analysis of existing data and new data received from
ongoing and future studies; the content and timing of decisions made by the
U.S. FDA and other regulatory authorities, investigational review boards at
clinical trial sites and publication review bodies; Infinity’s ability to
obtain and maintain requisite regulatory approvals and to enroll patients in
its clinical trials; cash requirements and unplanned cash expenditures;
development of agents by Infinity’s competitors for diseases in which Infinity
is currently developing its product candidates; adverse economic and market
conditions, and Infinity’s ability to obtain, maintain and enforce patent and
other intellectual property protection for any product candidates it is
developing. These and other risks which may impact management’s expectations
are described in greater detail under the caption “Risk Factors” included in
Infinity’s quarterly report on Form 10-Q filed with theSecurities and
Exchange Commission (SEC) onAugust 8, 2013, and other filings filed by
Infinity with theSEC. Any forward-looking statements contained in this press
release speak only as of the date hereof, and Infinity expressly disclaims any
obligation to update any forward-looking statements, whether as a result of
new information, future events or otherwise.

Contact:

Infinity Pharmaceuticals, Inc.
Jaren Madden, 617-453-1336
Jaren.Madden@infi.com
http://www.infi.com
 
Press spacebar to pause and continue. Press esc to stop.